Breast cancer (invasive) · line 2 · Olaparib monotherapy (BRCA-mutant HER2- breast: metastatic OR adjuvant high-risk early)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-OLAPARIB-BREAST |
| ID | IND-BREAST-TNBC-2L-BRCA-OLAPARIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-BREAST |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 SRC-OLYMPIAD-ROBSON-2017 |
Notes
ESCAT IA. OlympiAD established olaparib for germline BRCA1/2-mutant HER2- metastatic breast (≤2 prior chemo lines for metastatic; HR+ subset must have ≥1 prior endocrine line). For TNBC subset olaparib is typically ≥2L (after 1L pembro + chemo for PD-L1+ or chemo alone for PD-L1-). Talazoparib (EMBRACA) is the alternative PARPi — comparable efficacy, more anaemia, less GI. Patient preference and AE-profile drive olaparib-vs-talazoparib choice. UA access: olaparib reimbursed for breast indication; talazoparib not yet reimbursed.
Used By
Algorithms
ALGO-BREAST-TNBC-2L- ALGO-BREAST-TNBC-2L